Design, synthesis, <i>in silico</i> docking, ADMET and anticancer evaluations of thiazolidine-2,4-diones bearing heterocyclic rings as dual VEGFR-2/EGFR<sup>T790M</sup> tyrosine kinase inhibitors
Nada A. A. M. Aziz, Riham F. George, Khaled El‐Adl, Walaa R. Mahmoud
Abstract
Fourteen recent thiazolidine-2,4-diones bearing furan and/or thiophene heterocyclic rings have been designed, synthesized and assessed for their anticancer activities against four human tumor cell lines HepG2, A549, MCF-7 and HCT-116 targeting both VEGFR-2 and EGFR tyrosine kinases.
Topics & Concepts
ChemistrySorafenibIC50Docking (animal)StereochemistryPharmacophoreThiazolidineEGFR inhibitorsThiopheneA549 cellKinaseIn vitroBiochemistryEpidermal growth factor receptorCancer researchReceptorBiologyOrganic chemistryMedicineNursingHepatocellular carcinomaSynthesis and biological activityLung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancer